Related Experiment Video

Updated: Mar 28, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.8K

IGF-binding protein 2 is a candidate target of therapeutic potential in cancer

Xiaofeng Yao1,2, Shanshan Sun1,2, Xuan Zhou1,2

  • 1Department of Maxillofacial and Otorhinolaryngology Head & Neck Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|December 15, 2015
PubMed

Insights

Insulin-like growth factor-binding protein 2 (IGFBP2) is an oncogene in epithelial cancers. This review clarifies IGFBP2

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Insulin-like growth factor-binding protein 2 (IGFBP2) is recognized as an oncogene in various human epithelial cancers.
  • IGFBP2 plays a role in cancer metastasis and invasion by influencing key signaling networks.
  • The precise mechanisms of IGFBP2's involvement in tumorigenesis and progression require further elucidation.

Purpose of the Study:

  • To review and summarize current understanding of IGFBP2's function in cancer signaling pathways.
  • To discuss the potential of IGFBP2 as a therapeutic target in epithelial cancers.
  • To clarify the mechanistic roles of IGFBP2 in tumor progression and metastasis.

Main Methods:

  • Literature review and synthesis of existing research on IGFBP2.
  • Analysis of signaling pathways implicated in IGFBP2-mediated tumorigenesis.
  • Discussion of preclinical and clinical evidence regarding IGFBP2 as a therapeutic target.

Main Results:

  • IGFBP2 actively participates in multiple signaling pathways crucial for cancer development.
  • Evidence suggests IGFBP2 regulates processes involved in cancer cell invasion and metastasis.
  • Current research highlights IGFBP2's complex role in both initiating and advancing tumorigenesis.

Conclusions:

  • IGFBP2 is a significant factor in epithelial cancer progression.
  • Understanding IGFBP2's mechanisms offers potential for novel therapeutic strategies.
  • Targeting IGFBP2 may represent a promising approach for cancer treatment.
Keywords:
BiomarkerIGFBP2MetastasisTarget therapyTyrosine kinase inhibitor

More Related Videos

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.4K
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K